| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Peak Bio, Inc. | Director | Common Stock | 18,692 | $4,953 | $0.2650 | 25 Aug 2023 | Direct |
| Galera Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 96,000 | 24 Feb 2025 | Direct | ||
| Peak Bio, Inc. | Director | Warrant (Right to Purchase) | 35,000 | 25 Aug 2023 | Direct | ||
| Galera Therapeutics, Inc. | Director | Series B Preferred Stock | 8,326 | 30 Dec 2024 | Indirect |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| GRTX | Galera Therapeutics, Inc. | 24 Feb 2025 | 1 | $0 | 4 | Director | 26 Feb 2025, 16:52 |
| GRTX | Galera Therapeutics, Inc. | 30 Dec 2024 | 1 | $0 | 4 | Director | 02 Jan 2025, 16:08 |
| GRTX | Galera Therapeutics, Inc. | 30 Dec 2024 | 0 | $0 | 3 | Director | 02 Jan 2025, 16:05 |
| /report/000095017023047705-friedman-michael-r-2023-08-25 | Peak Bio, Inc. | 25 Aug 2023 | 0 | $0 | 3 | Director | 12 Sep 2023, 17:05 |